 The secondary endpoints will be the incidence of each component of the primary end-point; quality of life assessed by patients using Health-related quality of life questionnaire, i.e. the questionnaire which was used in the PROTECT study19, minor bleeding, a comparison of economic costs, an analysis of changes in cytokine concentrations natriuretic peptides and other inflammatory and pro-thrombotic cytokines before the procedure and at 6 months, and the relationship of LAA morphology to success of the LAA occlusion and the risk of systemic cardioembolic events. 